EN DE
Watch Sol Gel Technologies Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sol Gel Technologies Ltd (SLGL) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Sol Gel Technologies Ltd stock $8.19, price $63.40, that is 87.1% below the price, quality 65 out of 100. Rating: strongly overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Israel · ISIN IL0011417206

SG Sol Gel Technologies Ltd logo Thin data Nov 11, 2026

Sol Gel Technologies Ltd

SLGL · US

Far too expensive (fair value 87% below the price), but solid company and rising price: meets 2 of 3 rules.

Get notified free when this changes
Quality 65/100 
Rising price (uptrend) 
Generates free cash flow 
Mixed Growth (revenue 3y +70.9 %/yr in USD) 
Fair value $8.19 · Strongly overvalued 
Loss-making · -31.6% net margin (FY2025) 
Trails peers (2/7) 
Narrow moat 8/100 · thin data
Thin data 
Extreme value
Watch Sol Gel Technologies Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$104.00 $3.66 Fair Value $8.19 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $3.66 – $104.00 · fair‑value band $6.37 – $8.85 · the $63.40 price screens above the $8.19 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Sol Gel Technologies in your weekly email

Every Wednesday you see whether Sol Gel Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally.

Show moreShow less

The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.

It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome.

It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Stock analysis

Sol Gel Technologies Ltd (SLGL) currently trades at $63.40, while our model-based Fair Value estimate is $8.19, 87% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $8.28 per share, and 0 of the 7 models we run sit above the $63.40 price.

Bear case: the Multiples group reads lowest at $4.16, and 7 of the 7 models stay below the price. Data coverage for this calculation is low.

Scenario range: $6.37 (bear) to $8.85 (bull), the price of $63.40 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Sol Gel Technologies Ltd reported revenue of $19.4M in FY2025 versus $31.3M in FY2021, a compound −11.3%/yr. Reported net income was −$6.1M in FY2025.

Key figures

Market cap $202M Micro · EPS (TTM) $−5.61 · Net margin −31.6% · Return on equity −40.9% · Return on assets (EBIT) −30.8% (5-year average) · Operating margin −704% · Revenue growth (YoY) −96.6% · EPS growth (YoY) +488%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 35% below its 52-week high and 101% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −87%, SLGL screens richer than that median.

Fair Value models

Bear $6.37 Fair Value $8.19 Bull $8.85
Price $63.40 · Downside -87.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $7.76 $9.39 $14.11 74
Growth DCF $7.49 $9.79 $13.39 72
5Y Revenue Exit $5.53 $6.33 $7.94 67
All 7 models by family
DCF Models
FCF DCF $7.76 $9.39 $14.11 74
5Y Revenue Exit $5.53 $6.33 $7.94 67
10Y Revenue Exit $6.37 $8.19 $8.85 62
Multiples
EV/Revenue $3.83 $4.16 $4.49 52
Asset-Based
NCAV (Graham) $4.00 $6.07 $7.58 52
Growth DCF
Growth DCF $7.49 $9.79 $13.39 72
Rev-Margin DCF $5.71 $6.76 $9.02 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 65/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 29
How much profit the company makes from its sales and capital
Quality Growth 94
Are margins and returns getting better?
Cashflow 42
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 22
How calm the share price moves, does not count
Price momentum 47
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 74
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyOpaleye Management Inc.10% owner24× since Nov 20, 2025: 197,444 shares, avg. $56.83$11.2MSep 11, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 51/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+68.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+70.9%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+80.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−344.7% (2020) → −38.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.

SLGL screens overvalued: fair value 87% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Sol Gel Technologies Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 65 · Top 25%
Fair Value upside −87.1% · Bottom 25%
Profitability
Return on assets −20.5% · Above median
Net margin (12 months) −31.6% · Below median
Growth and dividend
Revenue growth (quarter YoY) −96.6% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 8.86× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $959.41 $1,275 +33% vs SLGL
Genmab A/S GMAB kr 3,530 kr 3,917 +11% vs SLGL
Vertex Pharmaceuticals Incorporated VRTX $547.03 $602.68 +10% vs SLGL
Samsung Biologics Co 207940 1,449,000 KRW 1,573,000 KRW +9% vs SLGL
argenx SE ARGX $977.58 $908.40 −7% vs SLGL
CSL Limited CSL A$204.54 A$183.54 −10% vs SLGL
Moderna, Inc MRNA $248.69 $158.70 −36% vs SLGL
BeOne Medicines AG 6160 HK$255.80 HK$152.80 −40% vs SLGL
Celltrion, Inc 068270 209,500 KRW 74,945 KRW −64% vs SLGL
Royalty Pharma plc RPRX $70.01 $19.01 −73% vs SLGL

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sol Gel Technologies Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sol Gel Technologies Ltd Fair Value". https://www.fairvalue-calculator.com/stock/SLGL

Frequently asked questions

Is Sol Gel Technologies Ltd (SLGL) overvalued or undervalued?
As of Nov 11, 2026, our model estimates a fair value of $8.19 versus a price of $63.40, about 87% lower (overvalued).
What is the fair value of SLGL?
Our model-based fair value for Sol Gel Technologies Ltd is $8.19 (as of Nov 11, 2026), built from audited fundamentals. The current price: $63.40.
What is the quality score of SLGL?
Sol Gel Technologies Ltd has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sol Gel Technologies Ltd (SLGL)?
Our model-based price target is the fair value of $8.19 (as of Nov 11, 2026) from 7 valuation models. Cautious scenario $6.37, optimistic scenario $8.85. It is a calculation from audited fundamentals, not an analyst target.
What is the Sol Gel Technologies Ltd stock forecast for 2026?
Our models put fair value at $8.19, about 87% lower versus a price of $63.40 (overvalued). Cautious scenario $6.37, optimistic scenario $8.85. The calculation is refreshed regularly with new filings.
What growth is priced into Sol Gel Technologies Ltd (SLGL)?
For today's price to be fair in a discounted-cash-flow model, Sol Gel Technologies Ltd would have to grow free cash flow by more than 80 % per year for five years (discount rate 13.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.2 % per year. As of Nov 11, 2026.
What discount rate (WACC) does the fair value of SLGL use?
Our models discount Sol Gel Technologies Ltd at 13.5 %: a base by market capitalisation (micro), damped by beta 1.24, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sol Gel Technologies Ltd that is more than 80 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.5 %) and the same formula as our fair value.
How much growth has Sol Gel Technologies Ltd (SLGL) delivered so far?
Over the past 5 years revenue at Sol Gel Technologies Ltd grew +17.2 % a year. The price currently implies free-cash-flow growth of more than 80 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sol Gel Technologies Ltd (SLGL) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Sol Gel Technologies Ltd (more than 80 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sol Gel Technologies Ltd (SLGL)?
The free-cash-flow yield on the price is 0.15 %: that much free cash flow Sol Gel Technologies Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sol Gel Technologies Ltd (SLGL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sol Gel Technologies Ltd it is $8.19 per share (as of Nov 11, 2026), against a price of $63.40. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Sol Gel Technologies Ltd stock overvalued or undervalued in 2026?
As of Nov 11, 2026, SLGL trades above its calculated fair value: price $63.40, fair value $8.19, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SLGL?
No. The price is what the market pays today ($63.40); the fair value is what the company's own numbers justify ($8.19). For Sol Gel Technologies Ltd the two are $55.21 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sol Gel Technologies Ltd worth?
The market values Sol Gel Technologies Ltd at about $202M (market capitalisation, as of Nov 11, 2026). Per share that is $63.40; our models calculate a fair value of $8.19 per share.
What do the bullish and bearish scenarios say about SLGL?
Our models span a range for Sol Gel Technologies Ltd: cautious scenario $6.37, base $8.19, optimistic $8.85 per share (as of Nov 11, 2026, price $63.40). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sol Gel Technologies Ltd (SLGL)?
Balance-sheet figures for Sol Gel Technologies Ltd (as of Nov 11, 2026): return on equity −40.9%. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is SLGL from its 52-week high?
Sol Gel Technologies Ltd trades at $63.40, about 35% below its 52-week high of $97.97 and 101% above the low of $31.50 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of $8.19 is for.
Which stocks are comparable to Sol Gel Technologies Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sol Gel Technologies Ltd stock attractive at the current price?
The data as of Nov 11, 2026: price $63.40, calculated fair value $8.19 (−87%), Quality Score 65/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SLGL calculated?
We run Sol Gel Technologies Ltd through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of $8.19 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.3% above its aggregate fair value. Sol Gel Technologies Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sol Gel Technologies Ltd (SLGL)?
The closing price on Nov 11, 2026 was $63.40. Our model-based fair value is $8.19, about 87% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sol Gel Technologies Ltd right now?
The price sits above even our optimistic bull case ($8.85). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Sol Gel Technologies Ltd

How large is the market capitalisation of Sol Gel Technologies Ltd (SLGL)?
The market capitalisation of Sol Gel Technologies Ltd is $202M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Sol Gel Technologies Ltd (SLGL)?
Earnings per share at Sol Gel Technologies Ltd are $−5.61. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sol Gel Technologies Ltd (SLGL)?
The net margin of Sol Gel Technologies Ltd is −31.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sol Gel Technologies Ltd (SLGL)?
The return on equity (ROE) of Sol Gel Technologies Ltd is −40.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sol Gel Technologies Ltd (SLGL)?
On an EBIT basis the return on assets of Sol Gel Technologies Ltd is −30.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sol Gel Technologies Ltd (SLGL)?
The operating margin of Sol Gel Technologies Ltd is −704% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sol Gel Technologies Ltd (SLGL)?
Revenue at Sol Gel Technologies Ltd is growing −96.6% versus a year earlier (3y avg +70.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sol Gel Technologies Ltd (SLGL)?
Earnings per share at Sol Gel Technologies Ltd are growing +488% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Sol Gel Technologies Ltd (SLGL) hold?
Sol Gel Technologies Ltd holds more cash than debt, $10.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Sol Gel Technologies Ltd in the live analysis

One click puts Sol Gel Technologies Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.